BR112022023352A2 - Composições, método para fornecer um agente bioativo, preparar uma pluralidade de partículas compósitas, tratar doença do olho seco e tratar uma doença ou afecção e método de uso recreativo - Google Patents

Composições, método para fornecer um agente bioativo, preparar uma pluralidade de partículas compósitas, tratar doença do olho seco e tratar uma doença ou afecção e método de uso recreativo

Info

Publication number
BR112022023352A2
BR112022023352A2 BR112022023352A BR112022023352A BR112022023352A2 BR 112022023352 A2 BR112022023352 A2 BR 112022023352A2 BR 112022023352 A BR112022023352 A BR 112022023352A BR 112022023352 A BR112022023352 A BR 112022023352A BR 112022023352 A2 BR112022023352 A2 BR 112022023352A2
Authority
BR
Brazil
Prior art keywords
lipid
disease
composite particles
treat
bioactive agent
Prior art date
Application number
BR112022023352A
Other languages
English (en)
Inventor
Shah Sunil
Ngu Sean
Original Assignee
Max Biology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Biology Co Ltd filed Critical Max Biology Co Ltd
Publication of BR112022023352A2 publication Critical patent/BR112022023352A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COMPOSIÇÕES, MÉTODO PARA FORNECER UM AGENTE BIOATIVO, PREPARAR UMA PLURALIDADE DE PARTÍCULAS COMPÓSITAS, TRATAR DOENÇA DO OLHO SECO E TRATAR UMA DOENÇA OU AFECÇÃO E MÉTODO DE USO RECREATIVO. Trata-se de uma composição que compreende uma pluralidade de partículas compósitas de lipídio-polímero que encapsulam um agente bioativo, em que as partículas compósitas de lipídio-polímero compreendem um copolímero em bloco, um lipídio selecionado do grupo que consiste em um lipídio neutro, um lipídio catiônico e um lipídio aniônico e um esterol, em que a pluralidade de partículas compósitas de lipídio-polímero tem um tamanho médio de partícula dentre 10 e 1000 nanômetros. Um método para preparar uma pluralidade de partículas compósitas de lipídio-polímero que encapsulam um agente bioativo, em que as partículas compósitas de lipídio-polímero compreendem um copolímero em bloco, um lipídio selecionado do grupo que consiste em um lipídio neutro, um lipídio catiônico e um lipídio aniônico e um esterol, em que a pluralidade de partículas compósitas de lipídio-polímero tem um tamanho médio de partícula dentre 10 e 1000 nanômetros, sendo que o método compreende homogeneizar o agente bioativo com o polímero para produzir uma solução homogeneizada e injetar o lipídio e o esterol na solução homogeneizada.
BR112022023352A 2020-05-18 2021-05-18 Composições, método para fornecer um agente bioativo, preparar uma pluralidade de partículas compósitas, tratar doença do olho seco e tratar uma doença ou afecção e método de uso recreativo BR112022023352A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063026306P 2020-05-18 2020-05-18
PCT/IB2021/054231 WO2021234548A1 (en) 2020-05-18 2021-05-18 Lipid-polymer compositions and methods of use

Publications (1)

Publication Number Publication Date
BR112022023352A2 true BR112022023352A2 (pt) 2023-05-02

Family

ID=76059949

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023352A BR112022023352A2 (pt) 2020-05-18 2021-05-18 Composições, método para fornecer um agente bioativo, preparar uma pluralidade de partículas compósitas, tratar doença do olho seco e tratar uma doença ou afecção e método de uso recreativo

Country Status (11)

Country Link
US (2) US20210353554A1 (pt)
EP (1) EP4153132A1 (pt)
JP (1) JP2023527162A (pt)
KR (1) KR20230022415A (pt)
CN (1) CN115968278A (pt)
AU (1) AU2021276644A1 (pt)
BR (1) BR112022023352A2 (pt)
CA (1) CA3183163A1 (pt)
IL (1) IL298282A (pt)
MX (1) MX2022014459A (pt)
WO (1) WO2021234548A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3864163T3 (fi) 2018-10-09 2024-05-03 Univ British Columbia Koostumukset ja järjestelmät, joihin sisältyvät transfektiokompetentit vesikkelit, joissa ei ole orgaanisia liuottimia eikä pesuaineita, sekä niihin liittyvät menetelmät

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
IL122290A0 (en) 1995-06-07 1998-04-05 Inex Pharmaceuticals Corp Lipid-nucleic acid complex its preparation and use
ATE246039T1 (de) * 1997-09-09 2003-08-15 Select Release L C Beschichtete teilchen, methode zu ihrer herstellung und verwendung
EP1096921B1 (en) 1998-07-20 2003-04-16 Protiva Biotherapeutics Inc. Liposomal encapsulated nucleic acid-complexes
US20120040809A1 (en) * 2010-08-11 2012-02-16 Formicola Thomas M Stretch-Out Roll Up Bar
CN101579312B (zh) * 2008-05-16 2013-04-10 中国科学院上海药物研究所 替尼泊甙脂质体及其制备方法
EA201791744A3 (ru) 2009-06-10 2018-07-31 Арбутус Биофарма Корпорэйшн Улучшенная липидная композиция
WO2014078470A1 (en) * 2012-11-14 2014-05-22 Cornell University Drug delivery compositions and methods targeting p-glycoprotein
KR20160094950A (ko) * 2013-10-31 2016-08-10 풀 스펙트럼 래버러토리즈, 리미티드 테르펜 및 칸나비노이드 제제
EP3137481B1 (en) * 2014-05-01 2022-07-06 Integral Biosystems LLC Membrane-adherent self-assembled systems for treatment of ocular disorders
CA2979184C (en) * 2015-03-10 2020-09-08 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
EP3424494A1 (en) * 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
CN108434101A (zh) * 2018-04-08 2018-08-24 武汉迈德森医药科技股份有限公司 一种新型的用于抗癌的Tivozanib脂质体、制剂及其制备方法和应用

Also Published As

Publication number Publication date
CA3183163A1 (en) 2021-11-25
WO2021234548A1 (en) 2021-11-25
MX2022014459A (es) 2023-02-27
JP2023527162A (ja) 2023-06-27
US20230355539A1 (en) 2023-11-09
IL298282A (en) 2023-01-01
EP4153132A1 (en) 2023-03-29
CN115968278A (zh) 2023-04-14
AU2021276644A1 (en) 2022-12-15
KR20230022415A (ko) 2023-02-15
US20210353554A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
Bahrami et al. Physico-mechanical and antimicrobial properties of tragacanth/hydroxypropyl methylcellulose/beeswax edible films reinforced with silver nanoparticles
Dhumal et al. Improvement of antimicrobial activity of sago starch/guar gum bi-phasic edible films by incorporating carvacrol and citral
Ghori et al. Okra extracts in pharmaceutical and food applications
Keller et al. Chitosan-based nanocomposites for the repair of bone defects
TWI699219B (zh) 軟膠囊皮膜用組成物
CN102389378B (zh) 一种用于化妆品的复合油脂微乳液及其制备方法
BR112022023352A2 (pt) Composições, método para fornecer um agente bioativo, preparar uma pluralidade de partículas compósitas, tratar doença do olho seco e tratar uma doença ou afecção e método de uso recreativo
Pandalaneni et al. Influence of milk protein concentrates with modified calcium content on enteral dairy beverage formulations: Physicochemical properties
BR112015010395A8 (pt) Composição para tratamento da pele com enxágue
US20150125494A1 (en) Cyclosporine-Containing Non-Irritative Nanoemulsion Ophthalmic Composition
KR20110007081A (ko) 소프트 캡슐 및 그 제조 방법
EP3785707A1 (en) Soft capsule film composition
EP2552413B1 (de) Neuartiges trägersystem für den transport von wirkstoffen in die haut
WO2014175289A1 (ja) 増粘性組成物
US20170292011A1 (en) Soft capsule shell
Maravić et al. Emulsion stabilizing capacity of sugar beet fibers compared to sugar beet pectin and octenyl succinate modified maltodextrin in the production of O/W emulsions: individual and combined impact
Suhaimi et al. Effects of formulation parameters on particle size and polydispersity index of orthosiphon stamineus loaded nanostructured lipid carrier
EP2243469B1 (de) Gefriergetrockneter Formkörper enthaltend Magnesiumascorbylphosphat
TW201332589A (zh) 軟膠囊皮膜
CN104387600A (zh) 一种面部注射用复合交联透明质酸钠凝胶微球的制备方法
JP2012529458A (ja) 活性化合物の送達のためのコロイド系の調製方法
MX2019000990A (es) Composiciones de tinta acuosas antibacterianas que comprenden poliester sulfonado con sodio y soluble en agua.
Deghiedy et al. Gamma radiation-assisted fabrication of bioactive-coated thyme nanoemulsion: A novel approach to improve stability, antimicrobial and antibiofilm efficacy
MY159317A (en) Treating idiopathic thrombocytopenic purpura with compositions comprising extracts of astragalus membranaceus
Sauerová et al. Hyaluronic acid as a modulator of the cytotoxic effects of cationic surfactants